Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
申请人:——
公开号:US20020143026A1
公开(公告)日:2002-10-03
The present invention provides compounds of formula I
1
and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.
[EN] CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES<br/>[FR] COMPOSES DE DIHYDROPYRIMIDINE CYANO-SUBSTITUES ET LEUR UTILISATION POUR TRAITER DES MALADIES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2002079169A1
公开(公告)日:2002-10-10
The present invention provides compounds of formula (I), formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.
[EN] 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN<br/>[FR] DÉRIVÉS DE 2-AMINOOXAZOLE EN TANT QU'ANTAGONISTES DE TRPVL UTILES POUR TRAITER LA DOULEUR
申请人:ABBOTT LAB
公开号:WO2009055749A1
公开(公告)日:2009-04-30
Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
申请人:——
公开号:US20030008888A1
公开(公告)日:2003-01-09
The present invention provides compounds of formula I
1
and pharmaceutically acceptable salts thereof.
The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.
Compounds of formula (I)
wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.